S
Shelley George
Researcher at Vertex Pharmaceuticals
Publications - 41
Citations - 5581
Shelley George is an academic researcher from Vertex Pharmaceuticals. The author has contributed to research in topics: Telaprevir & Ribavirin. The author has an hindex of 16, co-authored 41 publications receiving 5536 citations.
Papers
More filters
Journal ArticleDOI
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more
TL;DR: Telaprevir with peginterferon-ribavirin was associated with significantly improved rates of sustained virologic response in patients with HCV genotype 1 infection who had not received previous treatment, with only 24 weeks of therapy administered in the majority of patients.
Journal ArticleDOI
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode,Nicole Forestier,Geoffrey Dusheiko,Peter Ferenci,Stanislas Pol,Tobias Goeser,Jean-Pierre Bronowicki,Marc Bourlière,Shahin Gharakhanian,Leif Bengtsson,Lindsay McNair,Shelley George,Tara L. Kieffer,Ann D. Kwong,Robert S. Kauffman,John Alam,Jean-Michel Pawlotsky,Stefan Zeuzem +17 more
TL;DR: In this phase 2 study of patients infected with HCV genotype 1 who had not been treated previously, one of the three telaprevir groups had a significantly higher rate of sustained virologic response than that with standard therapy.
Journal ArticleDOI
Response-guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman,Steven L. Flamm,Nezam H. Afdhal,David R. Nelson,Mark S. Sulkowski,Gregory T. Everson,Michael W. Fried,Michael Adler,Hendrik W. Reesink,M. Martin,Abdul J. Sankoh,Nathalie Adda,Robert S. Kauffman,Shelley George,Christopher I. Wright,Fred Poordad +15 more
TL;DR: Among patients with chronic HCV infection who had not received treatment previously, a regimen of peginterferon-ribavirin for 24 weeks, with telaprevir for the first 12 weeks, was noninferior to the same regimen for 48 weeks in patients with undetectable HCV RNA at weeks 4 and 12, with an extended rapid virologic response achieved in nearly two thirds of patients.
Journal ArticleDOI
Telaprevir for previously treated chronic HCV infection.
John G. McHutchison,Michael P. Manns,Andrew J. Muir,Norah A. Terrault,Ira M. Jacobson,Nezam H. Afdhal,E. Jenny Heathcote,Stefan Zeuzem,Hendrik W. Reesink,Jyotsna Garg,Mohammad Bsharat,Shelley George,Robert S. Kauffman,Nathalie Adda,Adrian M. Di Bisceglie +14 more
TL;DR: In HCV-infected patients in whom initial peginterferon alfa-2a and ribavirin treatment failed, retreatment with telaprevir in combination with pegin terferonAlfa-1a and 2a and Ribavirin was more effective than retreatment without combination.
Journal ArticleDOI
Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors.
TL;DR: This review is focused on recent clinical trial results with specifically targeted antiviral therapy for HCV (STAT-C) protease and polymerase inhibitors, and focuses on the most advanced compounds in the HCV polymerase and HCV protease inhibitor classes.